Aurinia Pharmaceuticals Inc. (AUPH:NASDAQ) closed at $15.73 on November 13, 2026, down 2.96% on the day. The stock trades 18.3% below its 52-week high of $19.25 and 16.3% above its 52-week low of $13.52. Over the past year, it gained 2.5%. Aurinia Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, AUPH closed higher on 117 days (46%). Its best day was August 20, 2026 (+6.80%) and its worst was July 1, 2026 (-6.89%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 1 time.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Find more stocks like AUPH with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.